DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying DNA biomarkers in tissue samples from patients with osteosarcoma.
Genetic: DNA methylation analysis
Genetic: RNA analysis
Genetic: comparative genomic hybridization
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: mutation analysis
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma|
- Identification and validation of biomarkers with potential clinical utility
Biospecimen Retention: Samples With DNA
|Study Start Date:||August 2010|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- To comprehensively detect genomic, epigenomic, and transcriptomic aberrations in tissue samples from patients with osteosarcoma that may play a role in chemoresistance and metastasis using high-resolution genome-wide technologies.
- To identify recurrent genetic mutations involved in the pathogenesis of osteosarcoma, especially for the development of chemoresistance and metastatic tumors.
- To identify and validate these biomarkers for new therapeutic targets for patients with osteosarcoma, especially those with metastatic disease and whose tumors are resistant to standard chemotherapy.
OUTLINE: This is a multicenter study.
Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01190943
|Principal Investigator:||Ching C. Lau, MD, PhD||Texas Children's Cancer Center|